Abstract
Highlights
• Patients with severe COVID-19 disease are at risk of fungal co/secondary infections.
• COVID-associated pulmonary aspergillosis and candidemia are most common.
• We estimate impact of fungal infections on outcome in COVID ICU patients in England.
• Aspergillosis and candidemia independently increase COVID-19-associated mortality.
• Length-of-stay was extended in COVID-19 patients with either fungal infection.
• Patients with severe COVID-19 disease are at risk of fungal co/secondary infections.
• COVID-associated pulmonary aspergillosis and candidemia are most common.
• We estimate impact of fungal infections on outcome in COVID ICU patients in England.
• Aspergillosis and candidemia independently increase COVID-19-associated mortality.
• Length-of-stay was extended in COVID-19 patients with either fungal infection.
| Original language | English |
|---|---|
| Pages (from-to) | 579-613 |
| Number of pages | 35 |
| Journal | Journal of Infection |
| Volume | 84 |
| Issue number | 4 |
| Early online date | 4 Jan 2022 |
| DOIs | |
| Publication status | Published - 8 Apr 2022 |
Keywords
- CAPA
- COVID-19
- Fungal secondary infection
- HDU
- ICU
- Length of stay
- Mortality